Abstract
The genetic basis of amyotrophic lateral sclerosis (ALS) is still incompletely understood. Using two independent genetic strategies, we show here that a large part of ALS heritability lies in genes expressed in inhibitory and excitatory neurons, especially at splicing sites regulated by a defined set of RNA binding proteins including TDP-43 and FUS. We conducted a transcriptome wide association study (TWAS) and identified 59 loci associated with ALS, including 14 previously identified genes, some of them not previously reaching significance in genome wide association studies. Among the 45 novel genes, several genes are involved in pathways known to be affected in ALS such as mitochondrial metabolism (including ATP5H, ATP5D, BCS1L), proteostasis (including COPS7A, G2E3, TMEM175, USP35) or gene expression and RNA metabolism (including ARID1B, ATXN3, PTBP2, TAF10). Interestingly, decreased expression of NUP50, a constrained gene encoding a nuclear pore basket protein, was associated with ALS in TWAS (Zscore = −4, FDR = 0.034). 11 potentially pathogenic variants (CADD score > 20) in 23 patients were identified in the NUP50 gene, most of them in the region of the protein mediating interaction with Importin alpha, and including 2 frameshift mutations. In cells from two patients carrying NUP50 variants, we showed decreased levels of NUP50 protein. Importantly, knocking down Nup50 led to increased neuronal death associated with p62 and nucleoporin inclusions in cultured neurons, and motor defects in Drosophila and zebrafish models. In all, our study identifies alterations in splicing in neurons as a critical pathogenic process in ALS, uncovers several new loci potentially contributing to ALS missing heritability, and provides genetic evidence linking nuclear pore defects to ALS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Agence Nationale de la Recherche (ANR16CE920031, ANR16CE160015, ANR19CE170016, ANR20CE170008 to LD), by Fondation pour la recherche medicale (FRM, DEQ20180339179 and postdoctoral position to SaM), Axa Research Funds(rare diseases award 2019, to LD), Fondation Thierry Latran (HypmotALS, to LD and FR, Trials to FR), MNDA (Dupuis Apr16 852791 to LD), Association Francaise de Recherche sur la sclerose laterale amyotrophique (2016, 2021, to LD and ES), Radala Foundation for ALS Research (to LD and ES, and to FR). FR is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) ProjectID 251293561 Collaborative Research Center (CRC) and individual grants 443642953, 431995586 and 446067541. Genetic analyses were funded by the Association pour la Recherche sur la Sclerose laterale amyotrophique et autres maladies du motoneurone (ARSla,S.3200.ARSLA.1), the Association Francaise contre les Myopathies (AFMTelethon, 19466 to StM, 23646 to LD and ES). LD is USIAS fellow 2019. NUP50 WB/Immunofluorescence was funded by the Corona Stiftung Germany and through intramural funds to DYH. Drosophila work was supported by the EU Joint Programme Neurodegenerative Disease Research (JPND grant numbers ZonMW 733051075 (TransNeuro) and ZonMW 733051073 (LocalNMD) to ES) and an ERC consolidator grant (ERC2017COG 770244 to ES). This project has received funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation programme (grant agreement n 772376 EScORIAL). The collaboration project is cofunded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, to stimulate public private partnerships. FM received a PhD grant from the Brain Cognition Behaviour Doctoral School, (ED3C) at Sorbonne University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The details of the IRB/oversight body that provided approval for the research described are given below: PI,Country,IRB Millecamps,France,Paris Medical Research Ethics Committee of Assistance Publique Hopitaux de Paris Veldink,Netherlands,University Medical Center Utrecht Medical Ethics Committee Weber,Switzerland,Kantonale Ethikkomission des Kantons St Gallen Andersen,Sweden_Umea,Regional Ethical Review Board Couratier,France_Limoges,Ethics committee of Limoges University Hospital Ludolph,Germany_Ulm,Ethical committee of Ulm University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Annotation used in the manuscript will be made publicly available upon publication
